Literature DB >> 11563919

A structure-based design approach to the development of novel, reversible AChE inhibitors.

C Doucet-Personeni1, P D Bentley, R J Fletcher, A Kinkaid, G Kryger, B Pirard, A Taylor, R Taylor, J Taylor, R Viner, I Silman, J L Sussman, H M Greenblatt, T Lewis.   

Abstract

Chimeras of tacrine and m-(N,N,N-Trimethylammonio)trifluoroacetophenone (1) were designed as novel, reversible inhibitors of acetylcholinesterase. On the basis of the X-ray structure of the apoenzyme, a molecular modeling study determined the favored attachment positions on the 4-aminoquinoline ring (position 3 and the 4-amino nitrogen) and the favored lengths of a polymethylene link between the two moieties (respectively 5-6 and 4-5 sp(3) atoms). Seven compounds matching these criteria were synthesized, and their inhibitory potencies were determined to be in the low nanomolar range. Activity data for close analogues lacking some of the postulated key features showed that our predictions were correct. In addition, a subsequent crystal structure of acetylcholinesterase complexed with the most active compound 27 was in good agreement with our model. The design strategy is therefore validated and can now be developed further.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11563919     DOI: 10.1021/jm010826r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  Discovery of a new class of ionotropic glutamate receptor antagonists by the rational design of (2S,3R)-3-(3-carboxyphenyl)-pyrrolidine-2-carboxylic acid.

Authors:  Ann M Larsen; Raminta Venskutonytė; Elena Antón Valadés; Birgitte Nielsen; Darryl S Pickering; Lennart Bunch
Journal:  ACS Chem Neurosci       Date:  2010-11-12       Impact factor: 4.418

Review 2.  Medicinal chemistry of competitive kainate receptor antagonists.

Authors:  Ann M Larsen; Lennart Bunch
Journal:  ACS Chem Neurosci       Date:  2010-12-10       Impact factor: 4.418

3.  Inactivation of acetylcholinesterase by various fluorophores.

Authors:  Lilu Guo; Alirica I Suarez; Charles M Thompson
Journal:  J Enzyme Inhib Med Chem       Date:  2010-02       Impact factor: 5.051

4.  Molecular docking and receptor-specific 3D-QSAR studies of acetylcholinesterase inhibitors.

Authors:  Pran Kishore Deb; Anuradha Sharma; Poonam Piplani; Raghuram Rao Akkinepally
Journal:  Mol Divers       Date:  2012-09-21       Impact factor: 2.943

5.  Backdoor opening mechanism in acetylcholinesterase based on X-ray crystallography and molecular dynamics simulations.

Authors:  Benoît Sanson; Jacques-Philippe Colletier; Yechun Xu; P Therese Lang; Hualiang Jiang; Israel Silman; Joel L Sussman; Martin Weik
Journal:  Protein Sci       Date:  2011-06-10       Impact factor: 6.725

Review 6.  Discovery of Species-selective and Resistance-breaking Anticholinesterase Insecticides for the Malaria Mosquito.

Authors:  Paul R Carlier; Jeffrey R Bloomquist; Max Totrov; Jianyong Li
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

7.  Difluoromethyl ketones: Potent inhibitors of wild type and carbamate-insensitive G119S mutant Anopheles gambiae acetylcholinesterase.

Authors:  Eugene Camerino; Dawn M Wong; Fan Tong; Florian Körber; Aaron D Gross; Rafique Islam; Elisabet Viayna; James M Mutunga; Jianyong Li; Maxim M Totrov; Jeffrey R Bloomquist; Paul R Carlier
Journal:  Bioorg Med Chem Lett       Date:  2015-09-08       Impact factor: 2.823

8.  Conformational analysis and parallel QM/MM X-ray refinement of protein bound anti-Alzheimer drug donepezil.

Authors:  Zheng Fu; Xue Li; Yipu Miao; Kenneth M Merz
Journal:  J Chem Theory Comput       Date:  2013-02-18       Impact factor: 6.006

Review 9.  Hybrids: a new paradigm to treat Alzheimer's disease.

Authors:  Manjinder Singh; Maninder Kaur; Navriti Chadha; Om Silakari
Journal:  Mol Divers       Date:  2015-09-02       Impact factor: 2.943

10.  Novel bipharmacophoric inhibitors of the cholinesterases with affinity to the muscarinic receptors M1 and M2.

Authors:  Regina Messerer; Clelia Dallanoce; Carlo Matera; Sarah Wehle; Lisa Flammini; Brian Chirinda; Andreas Bock; Matthias Irmen; Christian Tränkle; Elisabetta Barocelli; Michael Decker; Christoph Sotriffer; Marco De Amici; Ulrike Holzgrabe
Journal:  Medchemcomm       Date:  2017-04-27       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.